MiNK Therapeutics, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. MiNK is a clinical-stage biopharmaceutical company developing allogeneic iNKT cell therapies. It reported no revenue; the filing presents operating expenses and losses, not revenue or gross margins.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 / prior date |
|---|---|---|
| Research and development expense | $2.55 million | $4.19 million |
| General and administrative expense | $1.28 million | $1.66 million |
| Operating loss | $3.83 million | $5.85 million |
| Net loss | $3.81 million | $5.69 million |
| Basic and diluted loss per share | $0.11 | $0.17 |
| Net cash used in operating activities | $2.54 million | $4.37 million |
| Cash and cash equivalents | $5.82 million | $3.37 million at Dec. 31, 2023 |
R&D expense fell 39%, attributed mainly to clinical-trial and preclinical timing and lower personnel costs. G&A expense fell 23%, primarily due to lower share-based compensation. Interest income declined to $17,000 from $168,000 as money-market balances and related earnings fell. No operating margin is meaningful because the filing reports no revenue.
At March 31, current assets were $6.00 million and current liabilities were $11.11 million, a working-capital deficit of approximately $5.11 million. Total assets were $6.89 million; stockholders’ deficit was $20.30 million. Liabilities included $11.84 million due to related parties and a $5.0 million Agenus note, carried at fair value of $4.21 million. Agenus agreed not to require repayment of the related-party balance before June 30, 2025.
Material changes, outlook, and risks
- MiNK received $5.0 million from Agenus under a convertible promissory note in March. The note bears 2% stated interest, is payable on demand on or after January 1, 2026, and may be repaid or converted at Agenus’ election following a qualified financing. A change of control triggers payment of 1.5 times outstanding principal plus accrued interest.
- After quarter-end, MiNK agreed to sell 4.64 million shares at $1.25 per share for approximately $5.8 million net of offering expenses; the filing said the transaction was expected to close May 14, 2024, subject to customary conditions. This financing adds liquidity but dilutes existing shareholders.
- Management expects the quarter-end cash plus the subsequent financing to cover liquidity needs for more than one year from issuance of the financial statements. However, MiNK disclosed substantial doubt about its ability to continue as a going concern for one year after filing, citing dependence on Agenus for services and deferred payments and Agenus’ own going-concern disclosure. Additional funding will be needed to support liquidity beyond one year. Potential sources include partnerships, licensing, grants, equity or debt; Agenus has indicated willingness to provide further loans if needed.
- MiNK expects continued losses as it advances its programs. It plans a randomized Phase 1/2 expansion study of agenT-797 in relapsed/refractory gastric cancer and expects to submit an IND for an engineered iNKT program in 2024. Timing and costs of trials, regulatory approvals, partnerships and potential cash inflows remain uncertain; no financial guidance was provided.
- The Walloon Region advance remains a $2.3 million current liability following a default judgment seeking repayment. The company also reported dependence on Agenus-provided services and facilities. It said there were no material changes to previously disclosed risk factors and no material legal proceedings.
Important facts for investors to verify
- Whether the May 2024 stock sale closed on the stated terms and how proceeds affect cash runway and share count.
- MiNK’s cash use, funding needs, and ability to maintain Agenus services given the going-concern disclosures of both companies.
- Terms, carrying value, repayment or conversion implications of the Agenus note and the $11.84 million related-party balance.
- Status and potential payment consequences of the Walloon Region judgment and $2.3 million liability.
- Clinical and regulatory progress, including the planned gastric-cancer trial and expected 2024 IND submission; early clinical and preclinical results are not assurances of future outcomes.